Key result
The Hypertension Prevalence Estimator Tool predicted expected hypertension prevalence with small differences compared to actual observed prevalence (range, -3.3% to 0.6%) across validation cohorts.
Why the study?
Does a hypertension prevalence estimator tool accurately predict expected hypertension prevalence in ambulatory care patient populations?
Observational (n=27,858)
Does a hypertension prevalence estimator tool accurately predict expected hypertension prevalence in ambulatory care patient populations?
A newly developed hypertension prevalence estimator tool using demographic and comorbidity data provides clinically useful estimates that health systems can use to inform quality improvement efforts.
Health systems are well positioned to identify and control hypertension among their patients. However, almost one third of US adults with uncontrolled hypertension are currently receiving medical care and are unaware of being hypertensive. This study describes the development and validation of a tool that health systems can use to compare their reported hypertension prevalence with their expected prevalence. Tool users provide the number of patients aged 18 to 85 years treated annually, stratified by sex, age group, race/ethnicity, and comorbidity status. Each stratum is multiplied by stratum-specific national prevalence estimates and the amounts are summed to calculate the number of expected hypertensive patients. The tool's validity was assessed by applying samples from cohorts with known hypertension prevalence; small differences in expected vs actual prevalence were identified (range, -3.3% to 0.6%). This tool provides clinically useful hypertension prevalence estimates that health systems can use to help inform hypertension management quality improvement efforts.
No takes yet. Share an insight, caveat, or question.
Ritchey et al. (2016) conducted an observational in Hypertension (n=27,858). Hypertension Prevalence Estimator Tool vs. Observed prevalence was evaluated on Difference between expected and actual hypertension prevalence (-3.3% to 0.6%). The Hypertension Prevalence Estimator Tool predicted expected hypertension prevalence with small differences compared to actual observed prevalence (range, -3.3% to 0.6%) across validation cohorts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: